Business Wire

MAXION-WHEELS

7.6.2019 14:11:08 CEST | Business Wire | Press release

Share
Dongfeng and Maxion Wheels Hold Groundbreaking Celebration for New Passenger Car Premium Aluminum Wheel Plant

Maxion Wheels, the world’s largest wheel manufacturer, with its new joint venture partner, Dongfeng Motor Parts and Components Group, held a groundbreaking ceremony on June 6, 2019 at the future site of their 22,000 square meters plant in Suizhou, China. The new company, Dongfeng Maxion Wheels Co., Ltd., was honored to share this important milestone with its distinguished guests including: government officials and company dignitaries, customers, suppliers and associates.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190607005238/en/

“With our new partner, Dongfeng Motor Parts and Components, this plant will serve future demand from global and Chinese vehicle manufacturers for locally-produced aluminum car wheels,” said Pieter Klinkers, Chief Executive Officer, Maxion Wheels. “Through our partnership with one of China’s largest automotive parts companies, we can quickly bring global aluminum wheel making expertise to the biggest vehicle market in the world.”

Kai Kronenberg, Vice President and Chief Representative Officer for Maxion Wheels in China added, “We estimate start of production to be by the end of 2020, with plans to produce two million die cast, bright-machined wheels a year.”

ABOUT MAXION WHEELS

Maxion Wheels, a division of Iochpe-Maxion S.A., is a leading wheel manufacturer for passenger cars, light trucks, buses, commercial trucks, and trailers. The Company also produces wheels for agriculture, as well as other off-highway applications. With more than 100 years of wheel-making experience and 10,000 employees globally, Maxion is the world's largest wheel manufacturer, producing almost 60 million wheels per year. The Company serves its global OEM customers from a vast, globally-connected network that includes 23 plants in 12 countries, and state-of-the-art technical centers in the Americas, Europe, and Asia. To learn more, please visit Maxion Wheels’ website at www.maxionwheels.com .

ABOUT DONGFENG MOTOR PARTS AND COMPONENTS GROUP

Dongfeng Motor Parts and Components Group Co., Ltd., headquartered in Shiyan, Hubei province, is a subsidiary of Dongfeng Motor Co., Ltd., and specialized in research & development, manufacturing and sales of auto parts, including chassis systems, cabin and body systems, electric drive systems, braking and intelligent driving systems, powertrain systems, thermal management systems, powertrain systems and lightweight technologies.

Dongfeng Motor Parts and Components Group Co. Ltd. has 14,000 employees, 38 subsidiaries, including a listed company named Dongfeng Electronic Technology Co., Ltd. (Stock Code: 600081), 1 overseas company and 14 joint ventures. The annual sales of the Group in 2018 were RMB 18 billion, which make it one of the largest auto parts suppliers in China.

Contact:

MAXION WHEELS MEDIA CONTACT: Colleen Hanley Global Director, Marketing and Communications Tel: +1 (248) 916-2477 Email: colleen.hanley@maxionwheels.com

DONGFENG MEDIA CONTACT: Zhou Jiazhi Chief of Communication, Corporate Culture Communication Department Dongfeng Motor Parts and Components Group Co. Ltd. Tel: +86 (0719) 8221814 Email: zhoujz@dfl.com.cn

Link:

ClickThru

Social Media:

https://www.facebook.com/maxionwheelsofficial/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 15:00:00 CEST | Press release

Joint Development Talks with Global Optical Communications companiesExpanding Partnerships to Provide Total Transceiver Solution1,800 Patents Secured for High-Performance Optical Communications Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is streng

vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release

Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye